Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617278514> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2617278514 startingPage "85" @default.
- W2617278514 abstract "Purpose To compare the short-term outcomes of intravitreal bevacizumab alone with the combination of intravitreal bevacizumab and intravitreal triamcinolone acetonide for the treatment of neovascular age-related macular degeneration (AMD). Patients and methods This randomized clinical trial was conducted on 48 eyes of 48 patients with subfoveal and juxtafoveal choroidal neovascularization secondary to AMD. The eyes were randomly assigned to receive combined intravitreal bevacizumab 1.25 mg with intravitreal triamcinolone acetonide 4 mg (group 1, 24 eyes) or intravitreal bevacizumab alone (group 2, 24 eyes). Assessment of best-corrected visual acuity (BCVA), optical coherence tomography, was carried out at baseline and repeated at all postoperative follow-up intervals (1 week, 1 month, 3 months, and 6 months) and fluorescein angiography was performed at baseline and repeated 1 month after treatment. Results The mean age of the patients was 60.83±6.32 years (range 50–70 years) and 50.0% of the patients were men in group 1. In group 2, the mean age of the patients was 58.33±6.49 years (range 50–72 years) and there were 13 men (54.2%). BCVA improved from 0.13±0.06 (range 0.103–0.152) to 0.23±0.13 (range 0.175–0.287) ( P =0.00) in group 1 whereas in group 2, no improvement in BCVA occurred as the baseline was 0.23±0.14 (range 0.167–0.286) and it was 0.21±012 (range 0.167–0.267) at the end of the follow-up (6 months) ( P =0.00). Mean±SD central macular thickness at baseline was 363.708±70.115 μm (range 332–420 μm) and reduced to 287.958±21.497 μm (range 250–317 μm) at 6 months postoperatively in group 1 ( P =0.00). However, in group 2, the mean±SD central macular thickness at baseline was 334.5±28.537 μm (range 305–410 μm) and moderately reduced to 304.25±23.265 μm (range 268–360 μm) at 6 months ( P =0.04). Conclusion The addition of triamcinolone acetonide to bevacizumab for the treatment of neovascular AMD seems to increase its short-term efficacy significantly." @default.
- W2617278514 created "2017-06-05" @default.
- W2617278514 creator A5069264548 @default.
- W2617278514 creator A5079018046 @default.
- W2617278514 date "2013-06-01" @default.
- W2617278514 modified "2023-09-28" @default.
- W2617278514 title "Comparing the combined effect of triamcinolone with bevacizumab with bevacizumab alone in neovascular age-related macular degeneration" @default.
- W2617278514 doi "https://doi.org/10.7123/01.jeo.0000431544.72499.fc" @default.
- W2617278514 hasPublicationYear "2013" @default.
- W2617278514 type Work @default.
- W2617278514 sameAs 2617278514 @default.
- W2617278514 citedByCount "0" @default.
- W2617278514 crossrefType "journal-article" @default.
- W2617278514 hasAuthorship W2617278514A5069264548 @default.
- W2617278514 hasAuthorship W2617278514A5079018046 @default.
- W2617278514 hasConcept C118487528 @default.
- W2617278514 hasConcept C141071460 @default.
- W2617278514 hasConcept C2776251621 @default.
- W2617278514 hasConcept C2776403814 @default.
- W2617278514 hasConcept C2776694085 @default.
- W2617278514 hasConcept C2777802072 @default.
- W2617278514 hasConcept C2778257484 @default.
- W2617278514 hasConcept C2778903070 @default.
- W2617278514 hasConcept C2780248432 @default.
- W2617278514 hasConcept C2781359195 @default.
- W2617278514 hasConcept C71924100 @default.
- W2617278514 hasConceptScore W2617278514C118487528 @default.
- W2617278514 hasConceptScore W2617278514C141071460 @default.
- W2617278514 hasConceptScore W2617278514C2776251621 @default.
- W2617278514 hasConceptScore W2617278514C2776403814 @default.
- W2617278514 hasConceptScore W2617278514C2776694085 @default.
- W2617278514 hasConceptScore W2617278514C2777802072 @default.
- W2617278514 hasConceptScore W2617278514C2778257484 @default.
- W2617278514 hasConceptScore W2617278514C2778903070 @default.
- W2617278514 hasConceptScore W2617278514C2780248432 @default.
- W2617278514 hasConceptScore W2617278514C2781359195 @default.
- W2617278514 hasConceptScore W2617278514C71924100 @default.
- W2617278514 hasIssue "2" @default.
- W2617278514 hasLocation W26172785141 @default.
- W2617278514 hasOpenAccess W2617278514 @default.
- W2617278514 hasPrimaryLocation W26172785141 @default.
- W2617278514 hasRelatedWork W1991419272 @default.
- W2617278514 hasRelatedWork W1994272890 @default.
- W2617278514 hasRelatedWork W1994973534 @default.
- W2617278514 hasRelatedWork W2022462690 @default.
- W2617278514 hasRelatedWork W2031496638 @default.
- W2617278514 hasRelatedWork W2061036262 @default.
- W2617278514 hasRelatedWork W2064500194 @default.
- W2617278514 hasRelatedWork W2070126836 @default.
- W2617278514 hasRelatedWork W2091612538 @default.
- W2617278514 hasRelatedWork W2150171454 @default.
- W2617278514 hasRelatedWork W2159452891 @default.
- W2617278514 hasRelatedWork W2159490014 @default.
- W2617278514 hasRelatedWork W2171529843 @default.
- W2617278514 hasRelatedWork W2275773128 @default.
- W2617278514 hasRelatedWork W2282206698 @default.
- W2617278514 hasRelatedWork W2332566027 @default.
- W2617278514 hasRelatedWork W2564113578 @default.
- W2617278514 hasRelatedWork W3031471749 @default.
- W2617278514 hasRelatedWork W3186145566 @default.
- W2617278514 hasRelatedWork W2786873666 @default.
- W2617278514 hasVolume "106" @default.
- W2617278514 isParatext "false" @default.
- W2617278514 isRetracted "false" @default.
- W2617278514 magId "2617278514" @default.
- W2617278514 workType "article" @default.